344 related articles for article (PubMed ID: 25532816)
1. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
Simpson DR; Mell LK; Cohen EE
Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816
[TBL] [Abstract][Full Text] [Related]
2. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
3. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
4. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
5. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
6. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham J
Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
[TBL] [Abstract][Full Text] [Related]
10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
11. NF-κB participates in chemokine receptor 7-mediated cell survival in metastatic squamous cell carcinoma of the head and neck.
Liu FY; Zhao ZJ; Li P; Ding X; Guo N; Yang LL; Zong ZH; Sun CF
Oncol Rep; 2011 Feb; 25(2):383-91. PubMed ID: 21165563
[TBL] [Abstract][Full Text] [Related]
12. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
13. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Papadimitrakopoulou V
J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
15. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
[TBL] [Abstract][Full Text] [Related]
16. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
Machiels JP; Schmitz S
Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
Price KA; Cohen EE
Oral Oncol; 2015 May; 51(5):399-408. PubMed ID: 25725588
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
Vander Broek R; Mohan S; Eytan DF; Chen Z; Van Waes C
Oral Dis; 2015 Oct; 21(7):815-25. PubMed ID: 24219320
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]